about
Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cellsToremifene versus tamoxifen for advanced breast cancerIdentification of polyproline II regions derived from the proline-rich nuclear receptor coactivators PNRC and PNRC2: new insights for ERα coactivator interactions.Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery.Loss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin.Small optic cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy.Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alphaZ-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERaDifferential response to α-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells.Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma.Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkersAn alternative mode of action of endocrine-disrupting chemicals and chemoprevention.Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Combination of siRNA-directed gene silencing with epigallocatechin-3-gallate (EGCG) reverses drug resistance in human breast cancer cellsTualang honey promotes apoptotic cell death induced by tamoxifen in breast cancer cell lines.Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system.PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cellsSystemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know.Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know.Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.A novel ERα-mediated reporter gene assay for screening estrogenic/antiestrogenic chemicals based on LLC-MK2 cells.Graphene as a nanocarrier for tamoxifen induces apoptosis in transformed cancer cell lines of different origins.WW domain-binding protein 2: an adaptor protein closely linked to the development of breast cancer.Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.αvβ3 integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo.Accurate prediction and elucidation of drug resistance based on the robust and reproducible chemoresponse communities.Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors.Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.An in vitro model for the development of acquired tamoxifen resistance.In vitro effects of tamoxifen on adipose-derived stem cells.QbD-Driven Development and Validation of a HPLC Method for Estimation of Tamoxifen Citrate with Improved Performance.Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.Inhibition of the MAPK pathway alone is insufficient to account for all of the cytotoxic effects of naringenin in MCF-7 breast cancer cells.Sequential release of drugs from hollow manganese ferrite nanocarriers for breast cancer therapy
P2860
Q23916703-1972500A-D5E4-4692-B37B-32397FBD937AQ24202053-18EA2DB1-529D-4CAD-A5D0-0AD58756D0E0Q30009591-12D70776-D9E3-4E74-95CB-AEE3DBDBC245Q30573300-1BCAA68E-0688-428B-AB11-F4B2C39D661DQ30841338-B6DAF4A4-F404-4AD6-BA1C-B51BB319BF90Q33239343-E1CCCBE7-AEB6-4EAC-B02B-D71FE82790D0Q33345012-0F7694CE-4FF3-4F91-A111-F0D03663C68DQ33710113-B20B89BF-5225-4978-BB69-A68B5ABC5022Q33831129-B3D34C3B-A4B9-462C-9D4A-F09A97CA0A56Q34137159-D3E00973-5036-4755-B695-EE41BE7541E8Q35578521-34A4C8DC-1DC8-4094-9F0B-A597B65323D5Q35751680-B2EB6921-6DEE-496C-B9B2-431FBE06F244Q35977805-F8D80CB1-4489-4673-93CF-1D2981A6310BQ36052802-801575F6-A36B-4322-9E9A-7E14F64BF22CQ36061821-1D53FA39-D04E-4ACB-9C3C-4F1DF7D12C57Q36520985-75F968A6-991E-46EF-A464-CFE1F10B35D5Q36651226-D6D003C2-359E-4233-9392-5D8B2D56E032Q36762899-6532E669-F809-44A3-B134-2DF7DA87B694Q37198963-9AA28C22-C930-48A2-BA9C-320AB2A9D0F0Q37461231-25798F85-BD72-431B-B62F-20A354DE30FBQ37671187-0614905E-5878-451B-A9E6-E51F2B904468Q38604479-2BC66C9D-1602-4784-9617-FE89A537BAF3Q38836713-F390BA7B-A893-40B2-B198-0E1B7F4B706AQ38933874-D9835743-6CB4-4BDC-A2B9-06F8C08954BDQ38973326-17CAD914-6D8C-4877-B32D-94042F21CE8BQ39439656-F20C26CA-55BE-4CAA-A4EB-32B720CDB246Q39445786-41A2AA54-56D8-4250-8389-7E88F2310C1DQ39618112-261002FE-11F4-4906-917B-D784AAF0C739Q40262820-357041D9-FA63-419A-80D1-363F822760BFQ44915727-79BBA215-6E7C-4448-9321-03F3A86C05D3Q47097144-3E7284CC-88CF-42EB-AA31-AC62D4AF2C24Q47343676-E2A89588-89F7-472D-9FAB-8308B37DC7CAQ48039896-4B6434FE-B5ED-476E-AEE0-63F12C893B05Q48711808-B01B9743-DFE6-428B-97B7-7D9FECC9E07AQ51538315-315FB38A-9889-42C0-99D1-67491037107CQ52938791-946549BC-C356-4DE6-A7ED-98F843804F2BQ53091829-2F398AED-3A85-4A4C-B169-926F4272B6D4Q53198290-E9043AFF-8B12-4D41-A667-E3B295F38ED8Q53760791-C3288E74-260C-4879-B60B-60F38889B1ADQ57173424-6B67ECA0-C605-41ED-BCAE-F7DC0638109D
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Tamoxifen ("Nolvadex"): a review.
@ast
Tamoxifen ("Nolvadex"): a review.
@en
type
label
Tamoxifen ("Nolvadex"): a review.
@ast
Tamoxifen ("Nolvadex"): a review.
@en
prefLabel
Tamoxifen ("Nolvadex"): a review.
@ast
Tamoxifen ("Nolvadex"): a review.
@en
P1476
Tamoxifen ("Nolvadex"): a review
@en
P2093
P304
P356
10.1016/S0305-7372(02)00036-1
P577
2002-08-01T00:00:00Z